Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics

Allogene Therapeutics, Inc. (ALLO): $9.75

0.44 (+4.73%)

POWR Rating

Component Grades














  • ALLO scores best on the Quality dimension, with a Quality rank ahead of 71.15% of US stocks.
  • ALLO's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • ALLO ranks lowest in Momentum; there it ranks in the 4th percentile.

ALLO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ALLO is 0 -- better than only 6.97% of US stocks.
  • ALLO's price/sales ratio is 5,990.27; that's higher than the P/S ratio of 99.91% of US stocks.
  • Revenue growth over the past 12 months for ALLOGENE THERAPEUTICS INC comes in at -99.36%, a number that bests just 0.69% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ALLOGENE THERAPEUTICS INC, a group of peers worth examining would be TSP, ARWR, AVIR, INDI, and DNLI.
  • ALLO's SEC filings can be seen here. And to visit ALLOGENE THERAPEUTICS INC's official web site, go to

ALLO Valuation Summary

  • ALLO's EV/EBIT ratio is -5; this is 158.14% lower than that of the median Healthcare stock.
  • Over the past 50 months, ALLO's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALLO.

Stock Date P/S P/B P/E EV/EBIT
ALLO 2022-11-25 6287.9 2.1 -5.0 -5.0
ALLO 2022-11-23 6188.7 2.1 -4.9 -4.9
ALLO 2022-11-22 6247.0 2.1 -4.9 -5.0
ALLO 2022-11-21 6013.8 2.0 -4.8 -4.8
ALLO 2022-11-18 5978.5 2.0 -4.7 -4.8
ALLO 2022-11-17 5844.1 2.0 -4.6 -4.7

ALLO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALLO has a Quality Grade of D, ranking ahead of 10.13% of graded US stocks.
  • ALLO's asset turnover comes in at 0.032 -- ranking 350th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ALLO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.032 1 -0.253
2021-03-31 0.031 1 -0.240
2020-12-31 0.000 NA -0.294
2020-09-30 0.000 NA -0.328
2020-06-30 0.000 NA -0.370
2020-03-31 0.000 NA -0.395

ALLO Price Target

For more insight on analysts targets of ALLO, see our ALLO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.57 Average Broker Recommendation 1.42 (Moderate Buy)

ALLO Stock Price Chart Interactive Chart >

Price chart for ALLO

ALLO Price/Volume Stats

Current price $9.75 52-week high $19.25
Prev. close $9.31 52-week low $6.43
Day low $9.34 Volume 2,011,604
Day high $9.94 Avg. volume 1,824,288
50-day MA $10.29 Dividend yield N/A
200-day MA $10.69 Market Cap 1.41B

Allogene Therapeutics, Inc. (ALLO) Company Bio

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.

ALLO Latest News Stream

Event/Time News Detail
Loading, please wait...

ALLO Latest Social Stream

Loading social stream, please wait...

View Full ALLO Social Stream

Latest ALLO News From Around the Web

Below are the latest news stories about ALLOGENE THERAPEUTICS INC that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) One-Time Cell Dosing with Proprietary Lymphodepletion (Single Dose FCA90) Resulted in 67% Overall Response Rate (ORR) and 58% Complete Response (CR) RateResponses in Patients that Received Single Dose FCA90 Were Durable with a 50% CR Rate at Both Six and 12 Months

Yahoo | November 29, 2022

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 28, 2022

Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's is How to Trade

The consensus price target hints at a 137.5% upside potential for Allogene Therapeutics (ALLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 22, 2022

15 Most Shorted Stocks Right Now

In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […]

Yahoo | November 17, 2022

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

Promising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T Cells and NK Cells Cloaking Approach Demonstrates Superiority to B2M Knock Out in a Syngeneic In Vivo Model Proprietary Approach Is One of Several Next Generation Technologies Being Pioneered at Allogene to Control Rejection SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp

Yahoo | November 10, 2022

Read More 'ALLO' Stories Here

ALLO Price Returns

1-mo -5.34%
3-mo -31.43%
6-mo 17.19%
1-year -47.27%
3-year -65.40%
5-year N/A
YTD -34.65%
2021 -40.89%
2020 -2.85%
2019 -3.53%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8401 seconds.